JP2013535487A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535487A5
JP2013535487A5 JP2013523278A JP2013523278A JP2013535487A5 JP 2013535487 A5 JP2013535487 A5 JP 2013535487A5 JP 2013523278 A JP2013523278 A JP 2013523278A JP 2013523278 A JP2013523278 A JP 2013523278A JP 2013535487 A5 JP2013535487 A5 JP 2013535487A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
acceptable salt
compound
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013523278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535487A (ja
JP6196154B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/046285 external-priority patent/WO2012018829A1/en
Publication of JP2013535487A publication Critical patent/JP2013535487A/ja
Publication of JP2013535487A5 publication Critical patent/JP2013535487A5/ja
Application granted granted Critical
Publication of JP6196154B2 publication Critical patent/JP6196154B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013523278A 2010-08-06 2011-08-02 C型肝炎ウイルス阻害剤の組み合わせ Expired - Fee Related JP6196154B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37139910P 2010-08-06 2010-08-06
US61/371,399 2010-08-06
PCT/US2011/046285 WO2012018829A1 (en) 2010-08-06 2011-08-02 Combinations of hepatitis c virus inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016072377A Division JP2016155844A (ja) 2010-08-06 2016-03-31 C型肝炎ウイルス阻害剤の組み合わせ

Publications (3)

Publication Number Publication Date
JP2013535487A JP2013535487A (ja) 2013-09-12
JP2013535487A5 true JP2013535487A5 (https=) 2014-09-04
JP6196154B2 JP6196154B2 (ja) 2017-09-13

Family

ID=45559795

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013523278A Expired - Fee Related JP6196154B2 (ja) 2010-08-06 2011-08-02 C型肝炎ウイルス阻害剤の組み合わせ
JP2016072377A Withdrawn JP2016155844A (ja) 2010-08-06 2016-03-31 C型肝炎ウイルス阻害剤の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016072377A Withdrawn JP2016155844A (ja) 2010-08-06 2016-03-31 C型肝炎ウイルス阻害剤の組み合わせ

Country Status (14)

Country Link
US (3) US20120196794A1 (https=)
EP (1) EP2600835B1 (https=)
JP (2) JP6196154B2 (https=)
KR (1) KR101846596B1 (https=)
CN (2) CN103153280B (https=)
AU (1) AU2011285890B2 (https=)
BR (1) BR112013002922A2 (https=)
CA (1) CA2807589C (https=)
EA (1) EA022303B1 (https=)
ES (1) ES2685174T3 (https=)
IL (1) IL224369B (https=)
MX (1) MX2013001170A (https=)
SG (2) SG187193A1 (https=)
WO (1) WO2012018829A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2691409B1 (en) * 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010042834A1 (en) * 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors

Similar Documents

Publication Publication Date Title
JP2013535487A5 (https=)
NZ599963A (en) Hcv combination therapy
JP2015529652A5 (https=)
JP2017008088A5 (https=)
CA2847355A1 (en) Methods for treating hcv
JP2016508134A5 (https=)
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
JP2014527061A5 (https=)
JP2011528713A5 (https=)
US20130172240A1 (en) Methods for treating hcv
JP2014508804A5 (https=)
EA201391337A1 (ru) Ингибиторы hsp90
WO2016134054A1 (en) Anti-viral compounds
JP2006511538A5 (https=)
JP2014148552A5 (https=)
RU2015101702A (ru) Фармацевтически активные соединения
NI202100031A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
US20140024613A1 (en) Methods for Treating HCV
WO2017040895A1 (en) Anti-viral compounds
JP2013532714A5 (https=)
JP2018521077A5 (https=)
WO2017040896A1 (en) Anti-viral compounds
JP2009532494A5 (https=)
JP2015526504A5 (https=)
WO2016182935A1 (en) Anti-viral compounds